Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 15;14(7):678.
doi: 10.3390/ph14070678.

Risk of Hospitalization for Adverse Drug Events in Women and Men: A Post Hoc Analysis of an Active Pharmacovigilance Study in Italian Emergency Departments

Affiliations

Risk of Hospitalization for Adverse Drug Events in Women and Men: A Post Hoc Analysis of an Active Pharmacovigilance Study in Italian Emergency Departments

Giada Crescioli et al. Pharmaceuticals (Basel). .

Abstract

This post hoc analysis of an Italian active pharmacovigilance study describes pharmacological differences of ADEs leading to emergency department (ED) visits and hospitalization in women and men. During the study period (January 2007-December 2018), 61,855 reports of ADEs leading to ED visits were collected. Overall, 30.6% of ADEs resulted in hospitalization (30% in women and 31% in men). Multivariate logistic regression showed that, among women, drug classes significantly associated with an increased risk of hospitalization were heparins (ROR 1.41, CI 1.13-176), antidepressants (ROR 1.12, CI 1.03-1.23) and antidiabetics (ROR 1.13, CI 1.02-1.24). Among men, only vitamin K antagonists (ROR 1.28, CI 1.09-1.50), opioids (ROR 1.30, CI 1.06-1.60) and digitalis glycosides (ROR 1.32, CI 1.09-1.59) were associated with a higher risk of hospitalization. Overall, older age, multiple suspected drugs and the presence of comorbidities were significantly associated with a higher risk of hospitalization. A significantly reduced risk of hospitalization was observed in both women and men experiencing an adverse event following immunization (ROR 0.36, CI 0.27-0.48 and 0.83, 0.42-0.74, respectively) compared to drugs. Results obtained from this real-world analysis highlight important aspects of drug safety between sexes.

Keywords: clinical pharmacology; emergency department; female; male; pharmacovigilance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Franconi F., Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: Interaction with biological differences between men and women. Br. J. Pharmacol. 2014;171:580–594. doi: 10.1111/bph.12362. - DOI - PMC - PubMed
    1. Farkouh A., Baumgartel C., Gottardi R., Hemetsberger M., Czejka M., Kautzky-Willer A. Sex-related differences in drugs with anti-inflammatory properties. J. Clin. Med. 2021;10:441. doi: 10.3390/jcm10071441. - DOI - PMC - PubMed
    1. Tran C., Knowles S.R., Liu B.A., Shear N.H. Gender differences in adverse drug reactions. J. Clin. Pharmacol. 1998;38:1003–1009. doi: 10.1177/009127009803801103. - DOI - PubMed
    1. Zopf Y., Rabe C., Neubert A., Janson C., Brune K., Hahn E.G., Dormann H. Gender-based differences in drug prescription: Relation to adverse drug reactions. Pharmacology. 2009;84:333–339. doi: 10.1159/000248311. - DOI - PubMed
    1. Schwartz J.B. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 2003;42:107–121. doi: 10.2165/00003088-200342020-00001. - DOI - PubMed

LinkOut - more resources